Introduction {#Sec1}
============

Iron balance is tenuous, and both iron deficiency and iron overload are deleterious. Iron homeostasis is orchestrated at the cellular as well as at the systemic level \[[@CR1]\]. At the cellular level, iron homeostasis is aimed at controlling the iron uptake, storage and export as well as the intracellular iron management and distribution. At the systemic level, iron homeostasis aims to meet the erythroid demands and keep the iron stores replete. The recent discovery of hepcidin (the iron regulatory hormone) has provided a consistent model of the iron homeostasis that allows for a better understanding of the importance of sensors at the cellular level for iron needs, as well as of the pathophysiology of the hereditary iron metabolism disorders such as hemochromatosis and anemia of chronic disorders (ACD).

Iron deficiency is by far the most common hematological disorder encountered in general practice. The basic approach to its diagnosis and management is well established and outlined in most medical and hematological texts. However, the patients suffering from anemia very often are affected by other additional medical problems, such as bacterial and viral infections, an inflammation or malignant tumors. Thus, an assessment of the body iron status seems to be more complex issue. Such conditions mentioned above exhibit a blunted erythropoietin (EPO) response by erythroid precursors, a decreased red blood cell survival, abnormalities in both iron absorption and the retention of iron in the one-nuclear cells, and they restrict the availability of iron to the erythroid precursors in the bone marrow.

ACD is a common problem particularly in patients with end-stage renal disease and it is present in a vast majority of patients treated with maintenance hemodialysis. The immunological basis of an inflammatory process in dialysis was presented among others in \[[@CR2]--[@CR4]\].

Fortunately, the renal anemia has been shown to be effectively alleviated or reversed by recombinant human erythropoietin (rHuEPO) which increases the speed of erythropoiesis by many factors \[[@CR5]\]. Doubling the erythropoietic activity would require a twofold iron demand. In such a state, the iron turnover will be a function of the iron stores and the erythropoietic activity of the bone marrow. The assessment of the iron requirements and an adequate iron supply are a prerequisite to an optimal response to rHuEPO.

A number of laboratory tests are employed to determine the iron status in patients receiving rHuEPO therapy, however, a valid method for the diagnosis of an iron deficiency anemia is still debatable. The iron availability may not keep pace with the iron demand for rHuEPO-enhanced erythropoiesis. This situation is known as a functional iron deficiency.

Because of the complexity of this issue, our emphasis in this article is put on the better understanding of the phenomenon of ACD and its diagnosis. For this purpose, we built a model of the body iron homeostasis formulated in the language of Petri net theory, which is precise enough for a possible analysis and allows a simulation of the process. A Petri net is a well-known mathematical structure, which has found many applications in the analysis of technical systems of many types. The concept of Petri nets was proposed in the early 1960s by Carl A. Petri \[[@CR6]\] in the area of technical systems as formalism suitable for modeling and the analysis of concurrent, asynchronous, distributed systems. With a rapid growth of computational biology in the last decade of the twentieth century, the structure of Petri nets was also used to model biological systems \[[@CR7]\]. Since that time, Petri nets are being used for describing and analyzing various biological processes, e.g., metabolic pathways \[[@CR8]\], signal transduction pathways \[[@CR9]\], and gene-regulatory networks \[[@CR10]\]. For an overview of the biological applications see, e.g., \[[@CR11], [@CR12]\]. Generally, the advantages of using Petri nets for the required model are on the one hand their feature to represent the system behavior even when the biological process is not understood in every detail by combining different abstraction levels in one model \[[@CR13]\]. And on the other hand, Petri nets comprise besides their firm mathematical foundation a visual representation of the model which enables a simulation of the system facilitating an intuitive comprehension of the biological pathways \[[@CR14]\].

In the following, a very brief introduction to the Petri net theory is given. A more detailed overview of the theory can be found in \[[@CR15], [@CR16]\].

A Petri net is a directed graph composed of two kinds of nodes and arcs connecting some of them but only nodes of different types can be connected in this way. One kind of nodes is given by the places which model the passive system components like states or biological species and they are represented by circles. The second kind of nodes is called transitions standing for the active system components as events or biological reactions, which in graphical representation are depicted as rectangles. Thus, the net arcs describe the interaction between the active and the passive system elements. Besides these structural elements, a Petri net has an additional dynamic component given by tokens, which can flow through the net. Generally, the tokens reside in places indicating that the corresponding state is fulfilled or, in a biological context, the corresponding substance is present in the system. A possible token flow is defined by the net structure. According to the arc direction every place (transition) may have a set of pre- and post-transitions (pre- and post-places). If all pre-places of a transition are marked with tokens, this transition is enabled to fire, i.e., the corresponding event or reaction may take place if all its reactants or other necessary chemical substances are available. With its firing the transition removes tokens from all its pre-places and puts tokens to all its post-places, i.e., the reaction removes a token of each its precursors and produces a token of each its products, since the tokens indicate the presence of the substance. In general, the number of moved tokens depends on the corresponding arc weight. But with relation to the model presented in this paper, we consider only ordinary Petri nets, i.e., all arcs are weighted with one. Altogether, arcs connect an event with its pre-conditions, which must be fulfilled to trigger this event and with its post-conditions, which will be fulfilled by occurring of that event. A transition without pre-places, a so-called input transition, is not determined by the tokens of the net and thus the event modeled by an input transition may take place at every time. In the case that a condition must be fulfilled but the firing of an adjacent transition does not remove any tokens from the corresponding place, these nodes are connected via two converse arcs. In the model, they are represented by bi-directional arrows and are called read arcs. Generally, a place in a Petri net may carry any integer number of tokens, indicating different degrees of fulfillment or different quantities of the corresponding substance. Since the number of pre-places of a transition has not to be equal to the numbers of its post-places, the total number of tokens in the net is not conserved. The distribution of the tokens over all places is called the marking of the net and describes a certain system state. Correspondingly, the initial marking represents the system state before the firing of any transition.

Materials and methods {#Sec2}
=====================

The model {#Sec3}
---------

To develop the Petri net model, at first all relevant biological interactions are translated into basic logical terms as implication, conjunction, disjunction, and negation. These logical terms are then unambiguously transformed into Petri net components. The graphical representation of a small Petri net example given in Fig. [1](#Fig1){ref-type="fig"} serves as an illustration. A conjunction-coupled implication is given with *p*0 ∧ *p*1 ⇒ *p*2, i.e., only if the places *p*0 and *p*1 are marked transition *t*2 may fire. Its firing puts a token at place *p*2. The two post-transitions of place *p*2, *t*3, and *t*4, are in conflict, i.e., one token at place *p*2 may enable both of these transitions but only one of them can fire. The firing of *t*3 additionally depends on the marking of place *p*5. If *p*5 is not marked, a token on place *p*2 leads to the firing of transition *t*4 (as the only enabled post-transition), i.e., *p*2 ∧ ¬*p*5 ⇒ *p*4. If there is a token on *p*5, a non-deterministic behavior results since the corresponding subnet represents an exclusive disjunction, i.e., *p*2 ∧ *p*5 ⇒ *p*3 ⊕ *p*4.Fig. 1A small Petri net containing seven places and nine transitions serving as an example. Input and output transitions are depicted as *flat rectangles*. The token of the initial marking is depicted by the *dot* on the place. For more details about it, its p-invariant and its three t-invariants, please see the text

Finally, an assembling of subnets built in that way gives the model. If there are some places without pre- or post-transitions in the net, some additional transitions are included representing the interface of the biological system to its surrounding (compare transitions *t*0, *t*1, *t*7, and *t*8 in Fig. [1](#Fig1){ref-type="fig"}). This modeling approach is introduced in \[[@CR17]\].

According to this approach, a Petri net is built modeling the body iron homeostasis. This model contains 47 places (*p*) and 57 transitions (*t*), shown in Fig. [2](#Fig2){ref-type="fig"}. For the sake of clarity, nodes are only named with their IDs. The corresponding names of the places and transitions are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} \[[@CR18]\], respectively, and they are self-explanatory formulated.Fig. 2The Petri net modeling the body iron homeostasis. Nodes are labeled with their IDs; their corresponding names are listed in Table [1](#Tab1){ref-type="table"}, and Table [2](#Tab2){ref-type="table"}, respectively. Logical places are tinted in grey and avoid immoderate arc crossing. A logical node is defined by its ID and exists in multiple copies in the net, which are logically identical. Thus, this model is a connected Petri net. Functional or spatial subunits are marked by accordingly labeled *ellipses*Table 1The names and IDs of the places of the modelIDPlace nameIDPlace name0LIP (in the small intestine)24IL-6 (cytokine)1Hem (Fe^2+^) in the small intestine25Less hepcidin2Hem (Fe^2+)^26Much hepcidin3Ferritin (Fe^3+^)27Much HAMP protein4Fe serum high28Inflammatory process5Fe serum medium29Ferritin (Fe^3+^)6Fe serum low30Available Fe^2+^7Fe^3+^31Fe^2+^ in serum (the one-nuclear cell)8Fe^2+^32Much Fpn9Fe^2+^ in serum33Erythrocyte synthesis support10Fe^3+^ in serum34Much EPO11HoloTf (Fe^3+^)35No inflammatory process12HoloTf (Fe^3+^) + TfR136Less TfR113ApoTf + TfR137TfR214LIP in pre-erythrocyte38Free HFE15ApoTf39Fe^2+^16Hem (Fe^2+^)40Fe^3+^17Erythrocyte41Much HFE protein18Hem (Fe^2+^) in the one-nuclear cell42Positive Fpn signal19Free Fe^2+^43Negative Fpn signal20LIP44Fe^2+^ in serum (one-nuclear cell)21ApoTf + TfR145Mitochondrium/enzymes22HoloTf (Fe^3+^) + TfR146Less Fpn23TfR1Some of these places are equally named (e.g. *p*8 and *p*39), but they are identified as different nodes, because they were not defined as logical nodes \[[@CR18]\]*LIP* labile iron pool, *HoloTf* holotransferrin, *ApoTf* apotransferrin, *IL-6* interleukin-6, *HAMP* hepcidin antimicrobial peptide, *Fpn* ferroportin, *TfR, TfR1, TfR2* transferrin receptors, *EPO* erythropoietin, *HFE* the hemochromatosis proteinTable 2The names and IDs of the transitions of the model \[[@CR18]\]IDTransition nameIDTransition name0Oxygenation via HO29IL-6 increase1Transport into the small intestine (transporter X)30Hepcidin increase (expressed in the liver)2Hem (Fe^2+^) uptake31HAMP expression3LIP split (IRP inactive)32(Fe^2+^) release4LIP split33Store (apoferritin) (IRP)5LIP split (IRP active)34Oxidation (Cp)6Transport into the small intestine (DMT1/NRAMP2/DCT1)35Fpn increase7(Fe^2+^) uptake36Fpn decrease/inhibition8Reduction by HCL37Positive signal9(Fe^3+^) uptake38Erythrocyte synthesis10Reduction by Dcytb39Signal for EPO synthesis in the kidneys11Transport out of the small intestine40Hepcidin inhibition12Loss41EPO decrease13Oxidation (Heph)42Normal state14Increase of low serum Fe level43Inflammatory process15Increase of medium serum Fe level44Fe^2+^ release16Binding of ApoTf + Fe^3+^45TfR1 inhibition (RNA degradation via IRP)17Endocytosis in pre-erythrocyte (RME) (TfR1)46TfR1 synthesis (RNA stabilization via IRP)18Exocytosis + cleavage47HoloTf (Fe^3+^) + TfR219Cleavage by low pH48Hepcidin increase (expressed in the liver)20Hem synthesis (ferrochelatase and protoporphyrin IX)49Apo Tf synthesis21Erythrocyte synthesis50Apo Tf synthesis inhibition22Phagocytosis in the one-nuclear cell51Fe consumption23Oxygenation52Fe consumption24Transport via Nramp153Transport into cytosol\
(DMT1/NRAMP2/CDT1)25Cleavage by low pH54(Fe^3+^) uptake parenteral26Exocytosis + cleavage55HFE expression27Endocytosis in the one-nuclear cell (RME)(TfR1)56Oxidation (Cp)28Transport out of the one-nuclear cell*HO* heme oxygenase, *LIP* labile iron pool, *IRP* iron responsive protein, *DMT1/NRAMP2/DCT1* divalent metal transporter-1 (natural resistance-associated macrophage protein-2 or divalent cation transporter-1), *Dcytb* duodenal cytochrome b, *Heph* hephaestin, *ApoTf* apotransferrin, *RME* receptor-mediated endocytosis, *TfR, TfR1, TfR2* transferrin receptors, *Nramp1* natural resistance-associated macrophage protein-1, *IL-6* interleukin-6, *HAMP* hepcidin antimicrobial peptide, *Cp* ceruloplasmin, *Fpn* ferroportin, *EPO* erythropoietin, *HoloTf* holotransferrin, *HFE* the hemochromatosis protein

Our model has been precisely described recently in \[[@CR18], [@CR19]\] and with using the time intervals in \[[@CR20]\]. In the presented model, we took into consideration the fact that anemia associated with a chronic inflammatory state is multi-factorial. During an inflammation, the body iron metabolism is changing. Iron is indispensable to living organisms; in vitro it is also conducive to bacterial growth \[[@CR21]\]. Some bacteria, in fact, have an iron uptake system that allows for the direct uptake of iron by means of a surface TfR. Within this context, no free iron is available in the circulation to promote the replication of microorganisms \[[@CR22]\]. In vivo, a number of mechanisms exist to limit the bacterial use of iron, notably an iron uptake via the reticuloendothelial system (the one-nuclear cells). So, an infectious and inflammatory disease commonly results a low serum iron concentration, which in consequence may lead to anemia.

Recently, it was found that hepcidin, a protein whose production is modulated in response to an inflammation, anemia, and hypoxia, is a link between anemia and inflammation \[[@CR23]\]. Hepcidin, by binding to ferroportin (Fpn), appears to block the iron uptake in the small intestine and the release from the one-nuclear cells thereby decreasing the delivery of iron to the red blood cells precursors in the bone marrow \[[@CR24]\].

In our model, a part of the network including correlations between the body iron and an inflammatory process was based on the Frazer and Anderson hypothesis \[[@CR25]\]. According to this, the regulation of the hepcidin expression depends on the ratio of transferrin receptor 1 (TfR1) on the one-nuclear cells' surface to the HoloTf (Fe^3+^) concentration in the serum. Hepatocyte surface HFE (the hemochromatosis protein) competes with HoloTf (Fe^3+^) for the binding on surface TfR1, which is a TfR2 competitor. Unbound surface HFE and a higher concentration of the HoloTf (Fe^3+^) TfR2 complex increase the hepatic hepcidin expression and its release. According to this model, an iron deficiency would lead to a decrease of the circulating HoloTf (Fe^3+^), and the concentration of free surface TfR1s would increase, resulting in a decreasing fraction of the free surface HFE and in a lower concentration of the HoloTf (Fe^3+^) TfR2 complex. This has been modeled in following way: HoloTf (Fe^3+^) + TfR2 (*t*47) leads via free HFE to a hepcidin increase (*t*48) that leads to a decrease of Fpn (*t*36). A too small amount of Fpn avoids the iron transport out of the small intestine (*t*11) as well as the iron transport out of the one-nuclear cell (*t*28). If the iron level is low, there is more TfR1 than TfR2 (*t*46) and, therefore, there is no free HFE. In the model, the iron release out of the ferritin-connected store requires that there is no inflammation in the system (*t*32 in the one-nuclear cell and *t*44 in the small intestine).

The analysis of the model {#Sec4}
-------------------------

The developed model has to be verified by an analysis of the net. A general overview of analysis possibilities is given, e.g., in \[[@CR13], [@CR25], [@CR26]\]. Further explanations for the analysis of this particular Petri net model are given in \[[@CR18], [@CR27]\].

At first, some structural properties are calculated based on the net structure. A main part of the further model validation consists in the invariant analysis based on the incidence matrix \[[@CR28]\]. Each entry of this (place × transition) matrix *C* gives the token change on a particular place by firing of the respective transition. Thus, no information about node connections via read arcs is included in *C.* The transition matrix for the simple net shown in Fig. [1](#Fig1){ref-type="fig"} is as follows (rows correspond to places and columns correspond to transitions):$$\documentclass[12pt]{minimal}
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                \begin{document}$$ C = \left[ {\begin{array}{*{20}c} 1 & 0 & { - 1} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 1 & { - 1} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & { - 1} & { - 1} & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 1 & 0 & 0 & 0 & { - 1} & 0 \\ 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & { - 1} \\ 0 & 0 & 0 & 0 & 0 & { - 1} & 1 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 1 & { - 1} & 0 & 0 \\ \end{array} } \right] $$\end{document}$$A p-invariant is calculated as a vector *y* satisfying the equation *y*· *C* = 0 and it is called a minimal p-invariant if it does not contain any other p-invariant. Such an invariant provides a set of places over which the weighted sum of tokens is constant. As a clear example, consider the Petri net in Fig. [1](#Fig1){ref-type="fig"}. It has one minimal p-invariant given by the vector (0, 0, 0, 0, 0, 1, 1), i.e., the places *p*5 and *p*6 form such an invariant and, therefore, the token placed on *p*6 in the initial marking circulates only between those two places (by firing of transitions *t*5 and *t*6). A required number of tokens (here one) has to be put in the initial marking at a place of each p-invariant to ensure that this subnet may contribute to the system behavior.

The iron homeostasis model contains four minimal p-invariants. Hence, the places *Fe serum medium* (*p*5)*, Much Fpn* (*p*32)*, Less hepcidin* (*p*25), *and TfR1* (*p*23) are marked with tokens already in the initial marking. Note that the tokens are put at one place of each p-invariant in a way representing an inactive state of the model. That means a medium level of iron, a high level of Fpn, a low level of hepcidin, and a higher amount of TfR1 compared with the amount of TfR2 is assumed to be the physiologically normal state of the system. These tokens contained in the initial marking of the net will circulate only between places of each minimal p-invariant. For example, the first p-invariant consists of the places *Fe serum high* (*p*4), *Fe serum medium* (*p*5), and *Fe serum low* (*p*6). Thus, the mentioned token will only circulate between those three places, indicating the level of iron in the serum. The second and the third minimal p-invariants, both consist of two places, which are *less hepcidin* (*p*25) and *much hepcidin* (*p*26), and *much Fpn* (*p*32), and *less Fpn* (*p*46), respectively. Each of the two tokens circulating between those places indicates the changed available quantity of hepcidin and Fpn, respectively. The fourth minimal p-invariant indicates by its token the form in which TfR1 is present in the system. It contains the six places *HoloTf* (*Fe*^*3*+^) + *TfR1* (*p*12), *ApoTf* + *TfR1* (*p*13), *ApoTf* + *TfR1* (*p*21), *HoloTf* (*Fe*^3+^) + *TfR1* (*p*22), *TfR1* (*p*23), and *less TfR1* (*p*36)*.* To distinguish these places see Fig. [2](#Fig2){ref-type="fig"}.

The minimal t-invariants of a net are calculated as vectors *x* satisfying the equation *C* · *x* = 0 and not containing any other such a vector and give a multiset of transitions which have altogether a zero effect on the marking, i.e., if all of them have fired the required number of times, a given marking is reproduced. Since the initial marking stands for that system state assumed as the normal state of the body, the t-invariants are a set of processes which lead again to that normal state after iron has been absorbed or other reactions have taken place.

The example net shown in Fig. [1](#Fig1){ref-type="fig"} again should serve as an illustration. It has three minimal t-invariants: given by vectors (0, 0, 0, 0, 0, 1, 1, 0, 0), (1, 1, 1, 1, 0, 0, 0, 1, 0), and (1, 1, 1, 0, 1, 0, 0, 0, 1). It means that the first of them contains the transitions *t*5 and *t*6 (representing the above-mentioned circulation of the token in the p-invariant). The second one consists of *t*0, *t*1, *t*2, *t*4, and *t*8 and the third minimal t-invariant includes *t*0, *t*1, *t*2, *t*3, and *t*7. The latter one is not feasible since it takes not into account the read arc between *t*3 and the empty place *p*5. A feasible t-invariant is a minimal t-invariant such that all transitions not belonging to this invariant. The reason that a minimal t-invariant is not a feasible t-invariant is an occurrence of read arcs, which are not reflected in the net incidence matrix (cf. \[[@CR17], [@CR18]\]). Thus, a processing of the minimal t-invariants combines these ones containing such connections with invariants providing tokens at these places see \[[@CR17]\]. This combination leading to feasible t-invariants results for the example net in the t-invariants: firstly, *t*5 and *t*6, secondly, *t*0, *t*1, *t*2, *t*4, and *t*8, and thirdly, *t*0, *t*1, *t*2, *t*3, *t*5, *t*6, and *t*7.

Since every possible invariant (i.e., p- and t-invariant) can be built as non-negative linear combination of minimal invariants in most cases it is sufficient to consider only the minimal ones. So, in our analysis only the minimal invariants are taken into account. Moreover, we focused on minimal t-invariants, since the analysis of them gives the most interesting biological results (at least in the case of our system).

In the model of the human body iron homeostasis, a processing of the 45 minimal t-invariants of the net leads to 85 feasible t-invariants. A specification of the feasible t-invariants can be found in Table [4](#Tab4){ref-type="table"}. The model is covered by feasible t-invariants, i.e., each transition is contained in such a t-invariant. Therefore, each modeled event takes place in the basic behavior of the net since the feasible t-invariants characterize this behavior \[[@CR17], [@CR28]\]. For the purpose of model verification, it has been checked and at last confirmed that each feasible t-invariant has a biological equivalent, see \[[@CR18]\].

Based on the feasible t-invariants it is decidable for each pair of transitions if they occur only together with each other in all of the feasible t-invariants or, if that is not the case, if they occur only in different feasible t-invariants. Following this information, the so-called MCT sets are built which consist of the processes linked with each other. In other words, the MCT-sets are calculated in such a way that two transitions belong to the same set if and only if they are elements of exactly the same feasible t-invariants. Transition which is not contained in any t-invariant form a single-element MCT-set. These sets support the verification of a biological meaning of feasible t-invariants (cf. \[[@CR17], [@CR18]\]). The MCT sets can be determined using the following simple algorithm:"Step 1. Compute *I(t*~*i*~), i.e., sets of t-invariants that share transition *t*~*i*~, for all t-invariants *t*~*i*~, e.g., create empty set for each transition and add t-invariants by iteration over all transitions feasible t-invariants.Step 2. Group equal sets *I*(*t*~*i*~), e.g., sort these sets lexicographically.Step 3. Create MCT-sets corresponding to grouped sets obtained in Step 2, if a set is empty, then corresponding transition creates separate MCT-set."

Example: if the result of Step 1 is: *I*(*t*~*1*~) = {*y*~2~, *y*~3~, *y*~7~}, *I*(*t*~2~) = {*y*~1~, *y*~3~, *y*~7~}, *I*(*t*~3~) = {*y*~2~, *y*~3~, *y*~7~}, *I*(*t*~4~) = {*y*~1~, *y*~3~, *y*~7~}, *I*(*t*~5~) = {*y*~2~, *y*~3~, *y*~7~}, *I*(*t*~6~) = ∅, *I*(*t*~7~) = ∅, ..., *I*(*t*~\|*T*\|~) = ∅, where *y*~*i*~ is a feasible t-invariant and \|T\| is the number of transitions, then the result of Step 2 is: *G* = {{*I*(*t*~1~), *I*(*t*~3~), *I*(*t*~5~)}, {*I*(*t*~2~), *I*(*t*~4~)}, *I*(*t*~6~), *I*(*t*~7~), ..., *I*(*t*~\|*T*\|~)} and the result of Step 3 is: MCT~1~ = {*t*~1~, *t*~3~, *t*~5~}, MCT~2~ = {*t*~2~, *t*~4~}, MCT~3~ = {*t*~6~}, MCT~4~ = {*t*~7~}, ..., MCT~\|*G*\|~ = {*t*~\|*T*\|~}.

The MCT-sets of the example net in Fig. [1](#Fig1){ref-type="fig"} should illustrate this grouping of transitions. Here, the net contains four MCT-set. They are given after an examination of the three feasible t-invariants named in the text above. Thus, the sets are: MCT-set 1 = {*t*5, *t*6}; MCT-set 2 = {*t*0, *t*1, *t*2}; MCT-set 3 = {*t*3, *t*7}; MCT-set 4 = {*t*4, *t*8}. The invariants can, therefore, be expressed in terms of MCT-sets. Generally, the transitions remaining as single once after the grouping mentioned above, represent the so-called trivial MCT-sets. In the following, they will be named as single transitions.

The MCT-sets of the homeostasis model are given in Table [3](#Tab3){ref-type="table"}. They are used also for Table [4](#Tab4){ref-type="table"} listing the feasible t-invariants (in this table the transitions composing each invariant and MCT-sets whose element a given invariant is also listed).Table 3The MCT-sets of the model and their biological meaningMCT-setContained transitionsBiological meaning10, 1, 2Hem(Fe^2+^) uptake24, 11, 12, 13, 14, 44, 52Iron transport through the small intestine35, 15, 51Iron level changes from low to high and decreases again48, 9(Fe^3+^) uptake510, 54Parenteral (Fe^3+^) uptake617, 18, 19, 20, 22, 23, 24, 53Iron pathway through the erythrocyte725, 26, 27Iron pathway through the one-nuclear cell828, 34Iron from the LIP to the serum929, 43Inflammation and IL-6 increase1030, 31, 55Inflammation caused increase of hepcidin1132, 33, 56Iron from LIP to store and its release1235, 36, 40Hepcidin decrease caused by much EPO, Fpn increase1345, 46, 47, 48TfR2 and free HFE caused hepcidin increase1449, 50ApoTf decrease caused by IL-6 increase*LIP* labile iron pool, *IL-6* interleukin-6, *EPO* erythropoietin, *Fpn* ferroportin, *TfR* transferrin receptor, *HFE* hemochromatosis proteinTable 4The feasible t-invariants of the modelt-clusterFeasible t-invariantMCT-setsTransitions1612, 3, 5, 6, 113, 6, 16, 38, 39, 42602, 3, 5, 6, 116, 16, 38, 39, 42592, 3, 4, 6, 113, 6, 16, 38, 39, 42582, 3, 4, 6, 116, 16, 38, 39, 42572, 3, 6, 113, 6, 7, 16, 38, 39, 42562, 3, 6, 116, 7, 16, 38, 39, 42492, 3, 5, 6, 113, 6, 16, 21, 37, 42482, 3, 5, 6, 116, 16, 21, 37, 42472, 3, 4, 6, 113, 6, 16, 21, 37, 42462, 3, 4, 6, 116, 16, 21, 37, 42452, 3, 6, 113, 6, 7, 16, 21, 37, 42442, 3, 6, 116, 7, 16, 21, 37, 42551, 2, 3, 6, 113, 16, 38, 39, 42541, 2, 3, 6, 1116, 38, 39, 42431, 2, 3, 6, 113, 16, 21, 37, 42421, 2, 3, 6, 1116, 21, 37, 422652, 3, 5, 6, 83, 6, 16, 38, 39, 42642, 3, 4, 6, 83, 6, 16, 38, 39, 42632, 3, 6, 83, 6, 7, 16, 38, 39, 42532, 3, 5, 6, 83, 6, 16, 21, 37, 42522, 3, 4, 6, 83, 6, 16, 21, 37, 42512, 3, 6, 83, 6, 7, 16, 21, 37, 42212, 5, 6, 86, 16, 38, 39, 42202, 4, 6, 86, 16, 38, 39, 42192, 6, 86, 7, 16, 38, 39, 42172, 5, 6, 86, 16, 21, 37, 42162, 4, 6, 86, 16, 21, 37, 42152, 6, 86, 7, 16, 21, 37, 42621, 2, 3, 6, 83, 16, 38, 39, 42501, 2, 3, 6, 83, 16, 21, 37, 42181, 2, 6, 816, 38, 39, 42141, 2, 6, 816, 21, 37, 423852, 3, 5, 12, 136, 16, 39, 42842, 3, 5, 12, 133, 6, 16, 39, 42832, 3, 4, 12, 136, 16, 39, 42822, 3, 4, 12, 133, 6, 16, 39, 42812, 3, 12, 136, 7, 16, 39, 42802, 3, 12, 133, 6, 7, 16, 39, 42791, 2, 3, 12, 1316, 39, 42781, 2, 3, 12, 133, 16, 39, 424412, 3, 5, 9, 10, 123, 6, 39, 42402, 3, 4, 9, 10, 123, 6, 39, 42392, 3, 9, 10, 123, 6, 7, 39, 42132, 5, 9, 10, 126, 39, 42122, 4, 9, 10, 126, 39, 42112, 9, 10, 126, 7, 39, 42381, 2, 3, 9, 10, 123, 39, 42101, 2, 9, 10, 1239, 425732, 3, 5, 7, 113, 6, 16, 42722, 3, 5, 7, 116, 16, 42712, 3, 4, 7, 113, 6, 16, 42102, 3, 4, 7, 116, 16, 42692, 3, 7, 113, 6, 7, 16, 42682, 3, 7, 116, 7, 16, 42671, 2, 3, 7, 113, 16, 42661, 2, 3, 7, 1116, 426772, 3, 5, 7, 83, 6, 16, 42762, 3, 4, 7, 83, 6, 16, 42752, 3, 7, 83, 6, 7, 16, 42252, 5, 7, 86, 16, 42242, 4, 7, 86, 16, 42232, 7, 86, 7, 16, 42741, 2, 3, 7, 83, 16, 42221, 2, 7, 816, 427372, 3, 53, 6, 37, 39, 41, 42362, 3, 43, 6, 37, 39, 41, 42352, 33, 6, 7, 37, 39, 41, 42332, 3, 53, 6, 42292, 3, 56, 42322, 3, 43, 6, 42282, 3, 46, 42312, 33, 6, 7, 42272, 36, 7, 42892, 56, 37, 39, 41, 4252, 56, 4282, 46, 37, 39, 41, 42726, 7, 37, 39, 41, 4242, 46, 42326, 7, 429341, 2, 33, 37, 39, 41, 42301, 2, 33, 42261, 2, 34261, 237, 39, 41, 4221, 2421019, 1442

Based on the information given in Table [4](#Tab4){ref-type="table"}, it is deducible which of the biological processes are independent of each other. In order to epitomize the information about the feasible t-invariants in a more compact way, the feasible t-invariants are grouped based on their similarities in the so-called t-clusters \[[@CR29]\]. Figure [3](#Fig3){ref-type="fig"} \[[@CR18]\] gives the dendrogram of the ten t-clusters of the 85 feasible t-invariants built using various clustering approaches. The dendrograms shown in parts (a)--(d) of the figure are results of application of standard clustering approaches, i.e., UPGMA-based approach and with an accordance of 65%, complete linkage with Euclidean distance metric, single linkage with percent disagreement metric and weighted pair group average with Euclidean distance metric, respectively. Clusters obtained using UPGMA method have been a base for grouping clusters obtained with the three remaining approaches, i.e., accordance in these approaches have been adjusted for clusters shown in part (a) for a comparison of the results. In addition, in part (e) of Fig. [3](#Fig3){ref-type="fig"} there is shown a dendrogram obtained using some non-standard clustering approach, which we call pathway-based approach, where feasible t-invariants having the same starting and ending transitions are considered as elements of the same cluster. As it can be noticed, the dendrograms shown in parts (a)--(d) of the figure are very similar to each other. The clusters obtained in all these cases are the same and the hierarchies differ not considerable.Fig. 3Dendrograms and comparison of clustering methods. *Numbers* on the right indicate the number of cluster. In parts **a**--**d**, there are the same t-clusters 1--10 listed in Table [4](#Tab4){ref-type="table"}---these clusters were computed using classical clustering methods based on size of common transition subsets. Clusters obtained in part **a** became a base for grouping clusters in **b**--**d** (accordance in **b--d** was adjusted for clusters obtained in **a** for better comparison of hierarchy); **a** UPGMA-based clustering with an accordance of 65%, **b** complete linkage with Euclidean distances metric, **c** single linkage with percent disagreement metric, **d** weighted pair group average with Euclidean distances metric. All clustered t-invariants were represented as 57-dimensional vectors (transitions 0-56) where each position is equal to 0 or 1 depending on existence of a transition in given feasible t-invariant. In part **e**, there are 9 clusters obtained from pathway-based method with transitions listed in Table [5](#Tab5){ref-type="table"}. Each cluster was represented as 9-dimensional vector (6 different input transitions and 3 different output transitions) where each position is equal to 0 or 1 depending on existence of input/output transition in given cluster

The most important conclusion following from these results is that various classical clustering methods give the same t-clusters which can be used for an analysis of the biological properties of the net.

Part (e) of Fig. [3](#Fig3){ref-type="fig"} shows the results of a clustering which are considerably different from those shown in parts (a)--(d). First of all, the number and the composition of the clusters differ from the previous one. The clusters hierarchy is also different. The reason is that the applied clustering procedure is based on a completely different idea. Table [5](#Tab5){ref-type="table"} shows the feasible t-invariants composing every of the t-clusters obtained with this method and also corresponding input and output transitions. They are the starting and ending transitions of a feasible t-invariant, on which the grouping procedure is based. Table [6](#Tab6){ref-type="table"} contains a comparison of the results of pathway-based clustering and the classical approaches. There are shown the numbers of common feasible t-invariants for all pairs of classical and non-classical t-clusters.Table 5List of t-invariants in clusters obtained from pathway-based clustering (all feasible t-invariants in a cluster have the same sets of input and output transitions)T-clusterFeasible t-invariantInput transitionsOutput transitions181, 80, 75, 69, 68, 63, 57, 56, 51, 45, 44, 39, 31, 27, 23, 19, 15, 11, 37, 421227, 354241, 123142, 4950485, 84, 77, 73, 72, 65, 61, 60, 53, 49, 48, 41, 33, 29, 25, 21, 17, 13, 554, 421259, 3754, 4241, 12683, 82, 76, 71, 64, 59, 58, 52, 47, 46, 40, 32, 28, 24, 20, 16, 12, 70, 49, 421278, 369, 4241, 12879, 78, 74, 67, 66, 62, 55, 54, 50, 43, 42, 38, 30, 26, 22, 18, 14, 10, 22, 421296, 342, 4241, 12Table 6Comparison of common transitions between pathway-based clustering (horizontal clusters 1--9) and classical clustering methods (vertical clusters 1--10)12345678914  4 4 4 24  4 4 4 32  2 2 2 42  2 2 2 52  2 2 2 62  2 2 2 721 2121  811 1111  9       3210  1      Numbers in the table are sizes of common t-invariant subsets within clusters

It seems that the non-classical t-clusters (i.e., the ones obtained using pathway-based clustering) are difficult to interpret from biological point of view, so in the further analysis the classical ones will be used.

Results and discussion {#Sec5}
======================

The main goal of our research was the formulation of the model, described above, which possibly most exactly would reflect the metabolism of the iron in the case of anemia and inflammation. In addition, on the basis of the analysis of the model's behavior we have attempted to make some observations concerning transferrin receptor and hepcidin.

Transferrin receptor {#Sec6}
--------------------

To the best of our knowledge, there is still no single biochemical parameter that is sensitive or specific enough to completely describe the distribution of iron in the human body. The routinely used laboratory tests, such as serum iron, total iron-binding capacity, transferrin saturation and serum ferritin are good indicators of the iron available for the erythropoiesis and for the iron stores but they are considerably influenced by a number of non-related conditions, e.g., the acute phase reactions, which may complicate the clinical interpretation of their results and create an inaccurate picture of the body iron status \[[@CR30]\]. In this situation, one of the proposed parameter that could be useful enough for the body iron assessment is the soluble transferrin receptor (sTfR) whose evaluation is an indirect measure of the quantity of the membrane transferrin receptor (TfR) \[[@CR31]\]. This assumption is based principally on the observed correlation between the concentration of the serum receptor molecule complexes with the transferrin and the ferrokinetic measurements of the erythron transferrin uptake \[[@CR32], [@CR33]\].

On the basis of the analysis of the models' behavior, we have attempted to check the influence of an inflammatory process on the level of TfR, i.e., TfR1 as well as TfR2. We have verified that an inflammatory process does not influence the TfR1 and TfR2 levels (no t-invariants contain both, the inflammatory process (*t*43) in MCT-set 9 in t-clusters 4 and 10 and the TfR regulation (*t*45, *t*46) in MCT-set 13 in t-cluster 3). That means that there is no connection between these two processes in the basic behavior of the model.

We have also tried to check whether EPO bears on the TfR concentration. In our model the TfR regulation was dependent partially on an increased EPO level. We have disclosed that in every t-invariant, which includes the TfR regulation (*t*45, *t*46), i.e., those of t-cluster 3, there occurs EPO production (*t*39), but on the other hand, EPO production also appears in t-invariants in which TfR is not regulated, namely in t-cluster 4 and partly in t-clusters 1 and 2. So, in the model the TfR regulation is correlated to an increased EPO level. On this basis, we can suggest that EPO, and also a supplementation of rHuEPO which contributes to an increase of the serum EPO, may influence the TfR concentration and because of this the usefulness of sTfR for assessment of the body iron status in patients supplemented with rHuEPO has a questionable value. Our results have supported some previous reports \[[@CR34]\] that rHuEPO intravenous dose administration influences the sTfR serum concentration in hemodialyzed patients. Some of the researchers suggested \[[@CR34]\] that the maintenance rHuEPO administration may not only enhance the erythropoiesis in the bone marrow but also may contribute to the serum sTfR concentration increase \[[@CR35]\]. Moreover, some of them implied that EPO itself raises intracellular calcium \[[@CR36]\] that may contribute to an acceleration of the TfR recycling. EPO may also regulate the rate of the truncation of TfR from the cell membrane \[[@CR34]\]. Other authors infer that the circulating sTfR levels may be useful in monitoring the iron status of mHD patients if the doses of rHuEPO are maintained constantly in those patients who are likely to be in a steady state erythropoietic stimulation \[[@CR37], [@CR38]\].

Another purpose of our study is to explore the factors determining the TfR1 concentration. Basing on the behavior of our model, we ascertained that a main factor affecting the concentration of this receptor was the concentration of the iron in the serum. The serum iron concentration (high serum iron concentration causes a TfR1 decrease and a TfR2 increase (*t*45) in MCT-set 13) mainly influences the TfR concentration (which is always independent of an inflammatory process represented in MCT-set 9, as has been mentioned above). The low serum iron concentration results in a TfR1 increasing (*t*46). The level of the serum iron concentration mainly influences the TfR regulation. A changed level of the Tf receptors influences the level of free HFE and via that way (in the case of a high level of TfR2) an increase of the hepcidin synthesis and a decrease/inhibition of Fpn (*t*45 and *t*46 are grouped in MCT-set 13 together with *t*47 (free HFE) and *t*48 (corresponding hepcidin increase with Fpn inhibition), see Table [3](#Tab3){ref-type="table"}).

We have also attempted to verify the hypothesis that the TfR1 concentration is a good marker of the erythropoietic activity in the human body. In our model if TfR1 is down regulated (included only in t-cluster 3), there is no iron uptake to pre-erythrocyte and, therefore, there is no hem synthesis (*t*20) which is contained in MCT-set 6 and occurs only in the t-clusters 1 and 2. Looking at this, we may suggest that the TfR1 serum concentration is a good marker of the erythropoietic activity.

Hepcidin {#Sec7}
--------

Another question, which we would like to answer, is: does the EPO concentration influence the hepcidin concentration? This issue is very important, particularly for the patients with an ESRD diagnosis with a diminished EPO production in the kidneys, an undergoing rHuEPO treatment. In our model, there is no connection between a lower EPO concentration and hepcidin. On the other hand, an increase of the EPO concentration (*t*38) depends on a low serum iron concentration, thus a high EPO concentration (*t*39) results in a hepcidin decrease (*t*40) connected with an increase of the Fpn (*t*35) level (the last two ones are transitions in MCT-set 12). So, on the basis of the behavior of our model it is difficult to say for certain that the serum EPO concentration influences the hepcidin concentration, but we suggest that it can be the case.

We have also tried to find how the concentration of hepcidin, HFE, and TfR is changing if there is a low serum Fe level (during an inflammatory process). Generally, the transition *t*52 (iron consumption which leads to a low iron level) in MCT-set 2 participates in every t-invariant (except of the first one which does not represent an iron flow through the net). From the point of view of the t-invariant calculation, a low iron level is needed in each of the three ways through the small intestine characterized by the three iron levels: high, medium, and low. If the serum iron level is low there is much EPO production (*t*38/*t*39) causing a hepcidin decrease (*t*40 in MCT-set 12) and a TfR1 increase. In this situation, TfR2 is not synthesized (*t*46, MCT-set 13) followed by no free HFE (*t*47, MCT-set 13), no corresponding hepcidin increase (*t*48, MCT-set 13) and Fpn decrease (*t*36, MCT-set 12). In Table [7](#Tab7){ref-type="table"}, the discussed biological conclusions following from the analysis of the model have been summarized.Table 7Summary of the biological conclusions following from the analysis of the model behaviorNo.ObservationsBiological conclusions1No t-invariants contain both, an inflammatory process, i.e., *t*43 in MCT-set 9 in t-clusters 4 and 10, and the TfR regulation, i.e., *t*45 band *t*46 in MCT-set 13 in t-cluster 3The inflammatory process does not influence the TfR1 and TfR levels.2In every t-invariant which includes the TfR regulation, i.e., *t*45 and t46 in t-cluster 3 there occurs EPO production, i.e., *t*39. On the other hand, *t*39 also appears in t-invariants in which TfR is not regulated, i.e., in t-cluster 4 and partly in t-clusters 1 and 2.The TfR regulation was dependant partially on an increased EPO level.3A level of Tf receptors influences the level of HFE and an increase of the hepcidin synthesis and a decrease/inhibition of Fpn---*t*45 and *t*46 are grouped in MCT-set 13 together with HFE, i.e., *t*47 band hepcidin increase, i.e., *t*48.A main factor affecting the concentration of TfR1 is the concentration of the iron in serum.4If TfR1 is down regulated (included only in t-cluster3), there is no iron uptake to pre-erythrocyte and therefore there is no hem synthesis, i.e., *t*20, which is contained in MCT-set 6 and occurs only in the t-clusters 1 and 2.The TfR1 serum concentration is a good marker of the erythropoietic activity.5Iron consumption leading to a low iron level, i.e., *t*52 in MCT-set 2 is included in every t-invariant except the first one, which does not represent an iron flow through the net.A low iron level is needed in each of the ways through the small intestine characterized by the three iron levels, i.e., high, medium, and low.

We can conclude that the analysis of the behavior of our Petri net-based model of the body iron homeostasis allows us to have the new insight into this complex process. Such an analysis is an interesting and valuable complement to the clinical research. On the other hand, it can also suggest some properties of the analyzed process which has not been realized previously. Moreover, since the formal model of the analyzed phenomenon is built on the basis of the current knowledge in a particular area its analysis can possibly also lead to a revision of this knowledge in cases when the obtained results do not agree with those following from classical experiments (but in this case the verification of the experiment results can be also necessary in same cases). For example, in \[[@CR39]\] it was found that the serum concentration of TfR is probably not influenced by EPO concentration but from our model it follows the opposite conclusion. The relation between these two concentrations was not explicitly used for building the model, hence it follows from the knowledge which was implicitly the basis for the model construction. The disagreement between the experimental and the theoretical (i.e., the ones following from the analysis of the model) results suggests the necessity of a revision of the knowledge of the human body iron homeostasis process (since it leads to conclusions contradicting the clinical results) or a verification of the clinical experiments. In both cases, the analysis of the theoretical model of the process leads to clarifying some of its aspects and better understanding this complex biochemical phenomenon. Following this direction of research, recently we have performed the new more accurate laboratory tests (concerning only patients with anemia of chronic disorders) whose results show that the conclusions concerning the relationship between TfR and rHuEPO coming from our model are correct (see "Validation of the model").

Validation of the model {#Sec8}
=======================

Materials and methods {#Sec9}
---------------------

In order to validate our model and verify whether the obtained results are confirmed in lab tests we used data obtained from 50 patients with end-stage renal disease, hemodialyzed in the Department of Nephrology, Transplantology and Internal Medicine, at Poznań University of Medical Sciences. To the analysis, we included only lab tests results from the patients suffering from anemia of chronic disorders and treated with rHuEPO. In every patient, the selected serum parameters, using ELISA-kits, like iron (Fe), soluble transferrin receptor (sTfR) which concentration is proportional to the total concentration of cellular TfR, hepcidin, erythropoietin concentration (EPO) were assessed. For the evaluation of the inflammatory status, we examined the levels of selected acute phase proteins, i.e., C-reactive protein (CRP), Interleukin-1 (IL-1), and Interleukin-6 (IL-6).

All tests were performed according to the manufacture's instruction. Ethical approval was obtained from the local ethics committee before the start of the study and all patients were asked for their verbal consent before the blood was taken.

We subjected the obtained results for statistical analysis using Statistica 8.0 (Stat Soft Inc., Tulsa, USA). The significance level was assumed to be equal to 0.05.

Analysis of the results of the laboratory tests {#Sec10}
-----------------------------------------------

The lack of the statistically significant correlations (see Table [8](#Tab8){ref-type="table"}) between sTfR and selected inflammatory variables confirms the results obtained on the basis of the analysis of the behaviour of our model, i.e., there is no connection between TfRs (transferrin receptors) and the inflammatory process.Table 8The associations between sTfR and selected inflammatory proteins obtained during laboratory tests from patients with anemia of chronic disordersVariableCRPIL-1IL-6sTfR*r* = −0.155*r* = 0.0085*r* = −0.2005*p* = 0.297*p* = 0.955*p* = 0.177*CRP* C-reactive protein, *IL-1* interleukin 1, *IL-6* interleukin 6, *r* Pearson's correlation coefficient, *p* value of the significance level

Based on the lab studies, we assessed the impact of rHuEPO therapy on the concentration of sTfR. We have obtained results (see Fig. [4](#Fig4){ref-type="fig"}) confirming our previous observations made on the models' behavior, i.e., the existence of a positive correlation between sTfR and dosage of rHuEPO.Fig. 4The scatter diagram (with histograms, i.e., the *upper* and the *right* panel, which are a graphical way of presenting the empirical distribution characteristics) shows the association between sTfR and rHuEPO. It illustrates the strong positive correlation (*r* = 0.37332, *p* = 0.01), which suggests a strong relationship between these variables. The *solid line* indicates the linear regression, and the *dotted line*---the 95% confidence interval. *sTfR* soluble transferrin receptor whose serum concentration is proportional to the total concentration of cellular TfR, *rHuEPO* mean weekly dose of recombinant human erythropoietin, *r* Pearson's correlation coefficient, *p* value of the significance level

Furthermore, as well as in our theoretical analysis, we found in lab analysis the relationship between low levels of serum iron and high levels of sTfR (Fig. [5](#Fig5){ref-type="fig"}). Other detected dependencies, i.e., between hepcidin and sTfR and also between serum EPO and hepcidin were in the lab test, not statistically significant, although similar trends like in behaviour of our model were preserved---an inverse relationship.Fig. 5The scatter diagram (with histograms, i.e., the *upper* and the *right panel*, which are a graphical way of presenting the empirical distribution characteristics) shows the association between sTfR and Fe. It illustrates the strong negative correlation (Spearman rank correlation coefficient *r* = −0.4284, *p* = 0.004), which suggests a strong inverse relationship between these variables. The *solid line* indicates the linear regression, and the *dotted line*---the 95% confidence interval. *sTfR* soluble transferrin receptor whose serum concentration is proportional to the total concentration of cellular TfR, *Fe* serum iron, *r* Pearson's correlation coefficient, *p* value of the significance level

In addition, during the lab tests we confirmed our results based on the analysis of the model concerning the statistically significant existence of a relationship between serum hepcidin and the dose of rHuEPO (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6The scatter diagram (with histograms, i.e., the *upper* and the *right panel*, which are a graphical way of presenting the empirical distribution characteristics) shows the association between hepcidin and rHuEPO. It illustrates the strong negative correlation (Spearman rank correlation coefficient *r* = −0.8368, *p* = 0.000), which suggests a strong inverse relationship between these variables. The *solid line* indicates the linear regression, and the *dotted line*---the 95% confidence interval. *rHuEPO* mean weekly dose of recombinant human erythropoietin, *r* Pearson's correlation coefficient, *p* value of the significance level

Summary {#Sec11}
=======

Anemia of chronic disorders is a very complex issue whose diagnosis is a not well-established procedure. To better understand this process and its influence on some other factors, a mathematical model of the body iron homeostasis has been built. The model has been formulated in the language of Petri net theory, which allows for its simulation and precise analysis, which, in turn, allows to answer some questions. On the basis of the net analyzed in this paper, we have found that there is no influence of inflammation on the concentration of the transferrin receptor. Moreover, the results of the model analysis suggest that erythropoietin and rHuEPO can influence the transferrin receptor levels. It was positively verified that TfR is a good marker of the erythropoietic activity. Also answers to questions if EPO influences the hepcidin concentration and how the concentration of hepcidin, HFE and TfR is changing during an inflammatory process have been found. The results obtained from the analysis of the model and the clinical research complement each other.
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